Henry Schein, Inc. $HSIC Shares Sold by P2 Capital Partners LLC

P2 Capital Partners LLC lowered its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 4.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 361,786 shares of the company’s stock after selling 15,000 shares during the quarter. Henry Schein makes up 4.6% of P2 Capital Partners LLC’s holdings, making the stock its 8th largest position. P2 Capital Partners LLC owned about 0.31% of Henry Schein worth $24,012,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Ameriprise Financial Inc. raised its stake in shares of Henry Schein by 3,275.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after buying an additional 2,199,695 shares during the period. Norges Bank acquired a new stake in Henry Schein in the 2nd quarter valued at $89,476,000. M.D. Sass LLC acquired a new stake in Henry Schein in the 2nd quarter valued at $79,201,000. Schroder Investment Management Group increased its holdings in Henry Schein by 149.3% in the 2nd quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock worth $114,243,000 after acquiring an additional 936,471 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in Henry Schein by 204.2% in the 2nd quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock worth $72,712,000 after acquiring an additional 668,182 shares in the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Henry Schein

In related news, CEO Stanley M. Bergman sold 43,812 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $81.31, for a total transaction of $3,562,353.72. Following the completion of the sale, the chief executive officer owned 383,803 shares of the company’s stock, valued at approximately $31,207,021.93. This represents a 10.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Philip A. Laskawy sold 2,844 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $80.36, for a total transaction of $228,543.84. Following the completion of the sale, the director owned 21,961 shares of the company’s stock, valued at approximately $1,764,785.96. The trade was a 11.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 104,556 shares of company stock valued at $8,476,351. Insiders own 1.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on HSIC. Robert W. Baird set a $100.00 price objective on shares of Henry Schein and gave the company an “outperform” rating in a report on Monday, February 23rd. Wall Street Zen cut shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Wells Fargo & Company upped their price target on shares of Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Finally, Morgan Stanley lifted their price objective on Henry Schein from $58.00 to $61.00 and gave the stock an “underweight” rating in a report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $85.58.

Henry Schein Trading Up 0.8%

Shares of HSIC stock opened at $75.57 on Friday. Henry Schein, Inc. has a fifty-two week low of $60.56 and a fifty-two week high of $89.29. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.76 and a current ratio of 1.38. The stock’s fifty day moving average is $78.21 and its two-hundred day moving average is $72.83. The firm has a market capitalization of $8.67 billion, a P/E ratio of 23.11, a PEG ratio of 2.22 and a beta of 0.88.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. The business had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Research analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.